Preview

Научно-практическая ревматология

Расширенный поиск

Европейский конгресс ревматологов, Берлин (6-9 июня 2012 г.)

https://doi.org/10.14412/1995-4484-2012-1105

Полный текст:

Список литературы

1. <div><p>Smolen J.S., Lamdewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis 2010;69:964-75.</p><p>Gabay C., Emery P., van Vollenhoven R. et al. Tocilizumab monotherapy is superior to adalimumab monotherapy in reducing activity in patients with rheumatoid arthritis: 24-week data from the phase 4 ADACTA trial. Ann Rheum Dis 2012;71(Suppl.3):152 [LB0003].</p><p>Dougados M., Kissel K., Amital H. et al. Double-blind study of tocilizumab plus methotrexate vs tocilizumab plus placebo in patients with active rheumatoid arthritis despiye prior methotrexate: progression of structural damage, quality of life, and physical function at 24 weeks. Arthr Rheum 2011;63(Suppl.):S1032-S1033.</p><p>Dougados M., Kissel K., Conaghan P.G. et al. Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate in RA: thew ACT-RAY study. Ann Rheum Dis 2012;71(Suppl.3):185 [THU0093].</p><p>Ostor A., Roman Ivorra J.A., Wollenhaupt J. et al. Comparison of tocilizumab as monotherapy or in combination with non-biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and inadequate response to anti-TNF agents. Ann Rheum Dis 2012;71(Suppl.3):372 [FRI0179].</p><p>Gomez-Reino J. Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. Rheumatology 2012;51:v31-v37.</p><p>Krieckaert C., Nurmohamed M.T., Wolbink G. Methotrexate reduces immunogenecity in adalimumab treated rheumatoid arthritis. Patients. Ann Rheum Dis 2012;71(Suppl.3):101 [OP0143].</p><p>Schiff M., Fleischmann R., Weinblatt M. et al. Abatacept versus adalimumab on backgroubd methotrexate in RA: one year results from AMPLE study. Ann Rheum Dis 2012;71(Suppl. 3):60 [OP0022].</p><p>Genovese M.C., Covarrubias A., Leon G. et al. Subcutaneous abatacept versus intravenous abatacept. A phase IIIb noninferiority study in patients with ibadequate response to methotrexate. Arthr Rheum 2011;63:2854-64.</p><p>Genovese M., Pacheco Tena C., Covarrubias Cobos A. et al. SC vs IV abatacept in RA: post-hoc efficacy analysis of long-term acquire (SC) data with AIM (IV) data. Ann Rheum Dis 2012;71(Suppl.3):378 [FRI0193].</p><p>Genovese M.C., Covarrubias A., Leon G. et al. Subcutaneous abatacept (ABA) versus intravenous ABA in patients with rheumatoid arthritis: long term data from ACQUIRE (Abatacept comparison of subcutaneous versus intravenous in inadequate responders to methotrexcate) trial. Arthr Rheum 2011;63 (Suppl.):S150.</p><p>Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008,67:1096-103.</p><p>Singh J.A., Furst D., Bharat A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthr Care Res 2012; 64:625-39.</p><p>O’Dell J.R., Mikuls T.R., Volbert R.A., Weinblatt M.E. Rheumatoid arthritis consensus conference; July 22-23, 2010: Clinical trial priorities and trial design issues. Arthr Rheum 2011;Apr 07, on line.</p><p>Boers M. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standart of care treatment including biologicals. Ann Rheum Dis 2010;69:4-6.</p><p>Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. акад. РАМН Е.Л. Насонова. М.: ИМА-ПРЕСС, 2011; 344 с.</p><p>Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80</p><p>Chatzidionysiou K., Lie E., Nasonov E. et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in Rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2011;on line.</p><p>Chatzidionysiou K., Lie E., Nasonov E. et al. Efficacy of different doses of Rituximab for the treatment of RA: data from the CERERRA collaboration. Ann Rheum Dis 2012;71(Supp.3):62 [OP0028].</p><p>Chatzidionysiou K., Lie E., Nasonov E. et al. Seropositivity and response to RTX: data from the CERERRA collaboration. Ann Rheum Dis 2012;71(Suppl.3):182 [THU0086].</p><p>Isaacs J.D., Cohen S.B., Emery P. et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on Rituximab clinical response: a meta-analysis. Ann Rheum Dis 2012; June 11, on line.</p><p>Emery P., Gottenberg J.-E., Sarzi-Puttini P. et al. Relative effectiveness of rituximab versus alternative TNF inhibitor in patients with rheumatoid arthritis and an inadequate response to a single previous TNF inhibitor: results from SWITCH-RA, a global, comparative-effectiveness, observational study. Ann Rheum Dis 2012;71(Suppl.3):381 [FRI0200].</p><p>Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010.</p><p>Van Vollenhoven R., Emery P., Bingham C.O. et al. Long-term safety of rituximab: 10-year follow-up in the rheumatoid arthritis global clinical trial programme. Ann Rheum Dis 2012;71(Suppl.3):195 [THU0120].</p><p>Goekoop-Ruiterman Y.P.M., De Vries-Bouwstra J.K., Allaart C.F. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthr Rheum 2005;52:3381 -90.</p><p>Van den Broek M., Dirven L., Klarenbeek N. et al. Clinical and radiological outcomes of four disease activity driven treatment strategy: 8-year results of the BeST study. Ann Rheum Dis 2012;71(Suppl. 3):106 [OP0154].</p><p>Rantalaiho V., Korpela M., Hannonen P. et al. Targeted treatment with combination DMARDs produces exelent clinical and radiographic long-term outcomes in early rheumatoid arthritis regadless of initial infliximab. The 5-year follow-up results of the NEORACO trial. Ann Rheum Dis 2012;71(Suppl. 3):103 [OP0147].</p><p>Karlsson J.A., Neovius M., Nilsson J.-A. et al. Addition of infliximab compared with addition of sulfasalasine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality of life results of the randomized, controlled Swefot trial. Ann Rheum Dis 2012;71(Suppl. 3):106 [0P0155].</p><p>Van Vollenhoven R.F., Ernestam S., Geborek P. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomized trial. Lancet 2009;374:459-66.</p><p>Van Vollenhoven R.F., Geborek P., Forslind K. et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded parallel-group Swefot trial. Lancet 2012, March 29.</p><p>Nam J.L., Villeneuve E., Hensor E.M.A. et al. Inhibition of structural damage with two intensive treatment strategies using infliximab or high dose intravenous steroid followed by treat to target in DMARD naive rheumatoid arthritis (the UDEA study). Ann Rheum Dis 2012;71(Suppl. 3):106 [OPC156].</p><p>Horslev-Petersen K., Hertland M.L., Junker P. et al. Remission rates substantially by adding adalimumab to methotrexate and intraarticular glucocorticoid in patients with early rheumatoid arthritis: 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA). Ann Rheum Dis 2012;71(Suppl.3):360 [FRI0148].</p><p>Hetland M.L., Stengaard-Pedersen K., Junker P. et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethason compared with methotrexate and intramuscular bethamethason in early active rheumatoid arthritis. An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthr Rheum 2006;54;1401-9.</p><p>Heimans L., Wevers-de Boer K.V.C., Visser K. et al. Remission after one year follow up of the IMPROVED study, a randomized clinical trial aiming at remission in patients with early rheumatoid and undifferentiated arthritis. Ann Rheum Dis 2012;71(Suppl. 3):329.</p><p>Kavanaugh A., Fleiscmann R.M., Emery P. et al. Clinical, functional and radiographic consequences of achiving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from randomized, controlled OPTIMA study. Ann Rheum Dis 2012;May 5, on line.</p><p>Kavanaugh A., Fleiscmann R.M., Emery P. et al. Efficacy of addition, or continuation, of adalimumab in patients who did not achive stable low disease activity with methotrexate or adalimumab plus methotrexate in the OPTIMA study. Ann Rheum Dis 2012;71(Suppl. 3):51 [SAT0122].</p><p>Emery P., Smolen J.S., Fleischmann R. et al. Achieving long-term comprehensive disease control with adalimumab and methotrexate in patients with early rheumatoid arthritis in the OPTIOMA study. Ann Rheum Dis 2012;71(Suppl.3):369 [FRI0171].</p><p>Smolen J.S.W., Emery P., Fleischmann R. et al. Biological free disease control in early RA: predictors of successful withdrawal of adalimumab after achiving stable low disease activity with ADA plus methotrexate - data from the OPTOMA study. Ann Rheum Dis 2012;71(Suppl.3):516 [SAT0134].</p><p>Detert J., Bastian N., Listing J. et al. Induction therapy with adalimumab plus methotrexate versus methotrexate monotherapy in recent onset rheumatoid arthritis (RA) - an investigator initiated randomized controlled trial. Ann Rheum Dis 2012;71(Suppl. 3):102 [ OP0145].</p><p>Jacobs J.W.G. Lessons for the use of non-biologic anchor treatment for rheumatoid arthritis in the era of biologic therapies. Rheumatology 2012;51:iv27-iv33.</p><p>Ospyants R., Karateev D., Panasyuk E. et al. Prediction of erosive disease in rheumatoid arthritis: utility of ultrasound joint score in patients with short disease duration. Ann Rheum Dis 2012;71(Suppl.3):611 [SAT0412].</p><p>Volkov A., Osipyants R., Panasyik E et al. Monitoring anti-interleukin 6 receptor antibody treatment in rheumatoid arthritis and prediction progressive structural damage of the wrist joints by ultrasonography. Ann Rheum Dis 2012;71 (Suppl.3):134 [OP0232].</p><p>Karateev D., Osipyants R., Panasyuk E. et al. Ultrasound defined remission in rheumatoid arthritis: association with clinical data, serologic parameters and structural damage. Ann Rheum Dis 2012;71(Suppl.3):606 [SAT0396].</p><p>Vasiliev V., Gorodetskiy V., Logvinenko O. et al. Characterisation of non-Hodgkin lymphomasd in rheumatic diseases. Ann Rheum Dis 2012; 71(Suppl.3):357 [FRI01380].</p><p>Sedyshev S., Vasilyev V., Kovrigina A. Characterization of the group of patients with IgG4-related systemic disease in Russian population. Ann Rheum Dis 2012;71(Suppl.3):292 [THU0405].</p><p>Nasonov E., Panasyuk E., Shikina E. et al. Local open-label multicenter study to evaluate the quality of life in patients with moderate to severe active rheumatoid arthritis and inadequate response to DMARDs when adding tocilizumab. Ann Rheum Dis 2012;71(Suppl.3):668.</p><p>Avdeeva A.S., Alexandrova E.N., Novikov A.A. et al. The high basal level antibodies to modified citrullinated vimentin (anti-MCV) - predictive factor of response to tocilizumab therapy in rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl.3):652 [AB0259].</p><p>Avdeeva A.S., Alexandrova E.N., Panasyuk E.Y. et al. Comparative effectiveness of tocilizumab (TCZ) and rituximab (RTM) using different disease activity indices (DAS 28, SDAI and CDAI) in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2012;71(Suppl.3):667 [AB0509].</p><p>Popkova T., Novikova D., Udachkina E. et al. Tocilizumab influence on the serum lipid profiles and rapid progression of intima media-thickness in patients with rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl.3):671 [AB0578].</p><p>Alexeeva E., Denisova R., Valieva S. et al. Efficacy and safety of Rituximab retreatment in refractory systemic juvenile idiopathic arthritis. Ann Rheum Dis 2012;71(Suppl.3):428 [FRI0338].</p><p>Alexeeva E., Denisova R., Valieva S. et al. Safety and efficacy of tocilizumab therapy in children with systemic oncet juvenile idiopathic arthritis. Ann Rheum Dis 2012;71(Suppl.3):258 [THU0302].</p><p>Novikova D.S., Popkova T., Udachkina R. et al. Duration and severety of the disease is important risk factor for cardiac autonomic neuropathy and arterial stiffness in women with rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl.3):170 [THU0052].</p><p>Myasoedova E., Myasoedova S., Musatova N. Trends in incidence and prevalence of rheumatoid arthritis in a russian population. Ann Rheum Dis 2012;71(Suppl.3):713 [AB1323].</p><p>Myasoedova Е., Myasoedova S., Obzherina S. et al. Reduced endothelium-independent vascular reactivity is indicative of carotid atherosclerosis in patients with rheumatoid arthritis without overt cardiovascular disease. Ann Rheum Dis 2012;71(Suppl.3):171 [THU0053].</p></div><br />


Для цитирования:


Насонов Е.Л., Denisov L.N., Amirdzhanova V.N. Европейский конгресс ревматологов, Берлин (6-9 июня 2012 г.). Научно-практическая ревматология. 2012;50(4):9-17. https://doi.org/10.14412/1995-4484-2012-1105

For citation:


Nasonov E.L., Denisov L.N., Amirdzhanova V.N. European Congress of Rheumatology, Berlin (6-9 June 2012). Rheumatology Science and Practice. 2012;50(4):9-17. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1105

Просмотров: 658


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)